P161 ROLES OF ANGIOPOIETINS 1 AND 2 ON ARTERIAL FUNCTION DURING A TREATMENT TRIAL IN PEOPLE WITH OR AT RISK OF DIABETES

DOI

10.1016/j.artres.2017.10.182How to use a DOI?

Abstract

Background/ Objective: Vascular growth factors angiopoietin-1 (Ang1) and -2 (Ang2) regulate vascular permeability and inflammation, Ang2 likely as Ang1’s selective antagonist. Their role before or in type 2 diabetes (pre-&T2D) is unknown. We hypothesised that higher circulating Ang1 and lower Ang2 (=lower Ang2/1 ratios) would be linked to increased arterial stiffness and its change over the trial, independent of blood pressure (BP).

Methods: ELISA assays were performed from 60 participants with all time-points of plasma samples from ‘VaSera’, a trial of single-centre, double-blind, parallel, randomised, controlled, 2x2 factorial design. Interventions were spironolactone and beetroot juice, a NO³⁻ donor, with doxazosin and placebo juice respectively to control for BP change (Δ) over the trial. Vascular measurements were aortic pulse wave velocity (aPWV), cardiac-ankle pulse wave velocity (CAVI), analysed by multiple regression adjusted for baseline BP and ΔBP over 6 months.

Results: Baseline Ang1 was positively while higher baseline Ang2 was negatively associated with baseline aoPWV at (ß = 0.37, p = 0.01; ß = −0.27, p = 0.047, respectively), independent of BP, BMI and DM status, so baseline r = −0.45 for the Ang2:1 ratio with aPWV, and r = 0.39 for ΔaPWV over the trial. Higher baseline Ang1 independently predicted decreased aoPWV over 6 months (ß = −0.44m/sec per ng/ml, p = 0.006). Angiopoietin concentrations were not associated with CAVI or BP.

Conclusions: Angiopoietins were related to baseline aPWV, independently of BP, and to ΔaPWV over the trial, also independent of BP change, but were unrelated to CAVI or BP. Monitoring and manipulating Angiopoietins may help arterial health in pre-&T2DM.

Open Access

This is an open access article distributed under the CC BY-NC license.

Download article (PDF)
View full text (HTML)

TY  - JOUR
AU  - K. Parkin
AU  - G. Slee
AU  - R. Gray
AU  - A. Webb
AU  - C. Mills
AU  - J.K. Cruickshank
PY  - 2017
DA  - 2017/12/06
TI  - P161 ROLES OF ANGIOPOIETINS 1 AND 2 ON ARTERIAL FUNCTION DURING A TREATMENT TRIAL IN PEOPLE WITH OR AT RISK OF DIABETES
JO  - Artery Research
SP  - 105
EP  - 105
VL  - 20
IS  - C
SN  - 1876-4401
UR  - https://doi.org/10.1016/j.artres.2017.10.182
DO  - 10.1016/j.artres.2017.10.182
ID  - Parkin2017
ER  -